We did not do a systematic review of scientific literature before designing the TOPICAL trial (in 2002), because at the time there were no other studies of first-line EGFR inhibitors in patients with advanced non-small-cell lung cancer (NSCLC) who were elderly or had poor performance status. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.